Mechanism and efficacy of drugs for Alzheimer's disease

Author:

Ye Chencheng

Abstract

Alzheimer's disease (AD) has become into a global concern to public health. Since it was first discovered in 1901, people have studied it for more than one hundred years, and many hypotheses have been proposed. However, its pathogenesis has not been completely revealed. In addition, the treatment and diagnosis of AD is a challenge worldwide, especially in low-income countries. Fortunately, however, some classical hypotheses have their validity, such as cholinergic injury hypothesis, Aβ cascade hypothesis and abnormal modification hypothesis of tau protein. And the drugs developed on the basis of these classical hypotheses have finally been proved to have therapeutic effects on Alzheimer's disease through continuous experiments by researchers. Among them, Aricept is a drug used in mild AD treating, which acts as cholinesterase inhibitor, while N-methyl-D-aspartic acid (NMDA) receptor antagonist Namenda is used to treat moderate or severe AD. This review reviews the background of Alzheimer's disease and its two available treatment medicines, called Aricept and Namenda, including drug mechanism, efficacy, safety and their pharmacokinetics.

Publisher

Darcy & Roy Press Co. Ltd.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3